Outlook Therapeutics prices 8.5M share offering under Form S-3
Outlook Therapeutics completed a public offering of 8,539,709 common shares via Form S-3 registration, with counsel providing legal opinion on share validity. The offering provides capital for the biopharmaceutical company's operations and pipeline development.
View filing at SEC.gov →